The clinical value of 123I-metaiodobenzylguanidine myocardial imaging in the diagnosis of dementia with Lewy bodies.
10.7507/1001-5515.202204082
- Author:
Weiting LIU
1
;
Xilan YAO
1
;
Xiaohong OU
1
Author Information
1. Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610041, P. R. China.
- Publication Type:Journal Article
- Keywords:
123I-metaiodobenzylguanidine;
Dementia with Lewy bodies;
Diagnostic biomarkers;
Myocardial imaging
- MeSH:
Humans;
Lewy Bodies;
3-Iodobenzylguanidine;
Lewy Body Disease/diagnostic imaging*;
Iodine Radioisotopes
- From:
Journal of Biomedical Engineering
2023;40(3):595-601
- CountryChina
- Language:Chinese
-
Abstract:
Metaiodobenzylguanidine (MIBG) is an analog of norepinephrine that accumulates in sympathetic nerve endings soon after intravenous administration. The degree of accumulation reflects the uptake, storage and release of transmitters by noradrenergic neurons. Myocardial imaging with 123I labeled MIBG ( 123I-MIBG) can be used to estimate the extent of local myocardial sympathetic nerve damage, which has been widely used in the diagnosis and treatment of various heart diseases. In recent years, numerous studies have been carried out on the application of 123I-MIBG in the diagnosis of degenerative diseases of the nervous system (such as Parkinson's disease and dementia of Lewy body), and have made some achievements. The purpose of this review is to summarize the current clinical application of 123I-MIBG myocardial imaging in the diagnosis of dementia with Lewy bodies, the problems in imaging technology and the possible research directions in the future, so as to provide valuable reference information for clinicians to reasonably and accurately apply this technology in the early diagnosis and discrimination of dementia.
